Pathobiologic implications of methylation and expression status of Runx3 and CHFR genes in gastric cancer

详细信息    查看全文

• 作者：Shi-Lian Hu (1) (2)
  Da-Bing Huang (1) (2)
  Yu-Bei Sun (3)
  Lei Wu (4)
  Wei-Ping Xu (4)
  Shi Yin (1) (2)
  Jiong Chen (1) (2)
  Xiao-Dong Jiang (1) (2)
  Gan Shen (5)
  
• 关键词：Gastric cancer ; Runx3 gene ; CHFR gene ; Methylation ; Methylation ; specific PCR
• 刊名：Medical Oncology
• 出版年：2011
• 出版时间：June 2011
• 年：2011
• 卷：28
• 期：2
• 页码：447-454
• 全文大小：481KB
• 参考文献：1. Machado JC, et al. E-cadherin gene (CDH1) promoter methylation as the second hit in sporadic diffuse gastric carcinoma. Oncogene. 2001;20:1525-. CrossRef
  2. Lee TL, et al. Detection of gene promoter hypermethylation in the tumor and serum of patients with gastric carcinoma. Clin Cancer Res. 2002;8:1761-.
  3. Leung WK, et al. Potential diagnostic and prognostic values of detecting promoter hypermethylation in the serum of patients with gastric cancer. Br J Cancer. 2005;92:2190-. CrossRef
  4. Oue N, et al. Distinct promoter hypermethylation of p16INK4a, CDH1, and RAR-beta in intestinal, diffuse-adherent, and diffuse-scattered type gastric carcinomas. J Pathol. 2002;198:55-. CrossRef
  5. Balmain A. Cancer: new-age tumour suppressors. Nature. 2002;417:235-. CrossRef
  6. Kim TY, et al. Methylation of RUNX3 in various types of human cancers and premalignant stages of gastric carcinoma. Lab Invest. 2004;84:479-4. CrossRef
  7. Jiang Y, Tong D, Lou G, Zhang Y, Geng J. Expression of RUNX3 gene, methylation status and clinicopathological significance in breast cancer and breast cancer cell lines. Pathobiology. 2008;75:244-1. CrossRef
  8. Subramaniam MM, et al. RUNX3 inactivation by frequent promoter hypermethylation and protein mislocalization constitute an early event in breast cancer progression. Breast Cancer Res Treat. 2009;113:113-1. CrossRef
  9. Nishida N, et al. Aberrant methylation of multiple tumor suppressor genes in aging liver, chronic hepatitis, and hepatocellular carcinoma. Hepatology. 2008;47:908-8. CrossRef
  10. Li QL, et al. Causal relationship between the loss of RUNX3 expression and gastric cancer. Cell. 2002;109:113-4. CrossRef
  11. Toyota M, et al. Epigenetic inactivation of CHFR in human tumors. Proc Natl Acad Sci USA. 2003;100:7818-3. CrossRef
  12. Corn PG, et al. Frequent hypermethylation of the 5-CpG island of the mitotic stress checkpoint gene Chfr in colorectal and non-small cell lung cancer. Carcinogenesis. 2003;24:47-1. CrossRef
  13. Scolnick DM, Halazonetis TD. Chfr defines a mitotic stress checkpoint that delays entry into metaphase. Nature. 2000;406:430-. CrossRef
  14. Sobin LH, Wittekind C. TNM classification of malignant tumors. 5th ed. International Union Against Cancer (UICC): New York; 1997.
  15. Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA. 1996;93:9821-. CrossRef
  16. Shibata Y, et al. Chfr expression is downregulated by CpG island hypermethylation in esophageal cancer. Carcinogenesis. 2002;23:1695-. CrossRef
  17. Homma N, et al. Spreading of methylation within RUNX3 CpG island in gastric cancer. Cancer Sci. 2006;97:51-. CrossRef
  18. Gao YJ, Xin Y, Zhang JJ, Zhou J. Mechanism and pathobiologic implications of CHFR promoter methylation in gastric carcinoma. World J Gastroenterol. 2008;14:5000-. CrossRef
  19. Wang L, et al. Transcription factor Sp1 expression is a significant predictor of survival in human gastric cancer. Clin Cancer Res. 2003;9:6371-0.
  20. Sato F, Meltzer SJ. CpG island hypermethylation in progression of esophageal and gastric cancer. Cancer. 2006;106:483-3. CrossRef
  21. Lau QC, et al. RUNX3 is frequently inactivated by dual mechanisms of protein mislocalization and promoter hypermethylation in breast cancer. Cancer Res. 2006;66:6512-0. CrossRef
  22. Ku JL, et al. Promoter hypermethylation downregulates RUNX3 gene expression in colorectal cancer cell lines. Oncogene. 2004;23:6736-2. CrossRef
  23. Tamura G. Promoter methylation status of tumor suppressor and tumor-related genes in neoplastic and non-neoplastic gastric epithelia. Histol Histopathol. 2004;19:221-.
  24. Honda T, et al. Promoter hypermethylation of the Chfr gene in neoplastic and non-neoplastic gastric epithelia. Br J Cancer. 2004;90:2013-. CrossRef
  25. Waki T, et al. Promoter methylation status of DAP-kinase and RUNX3 genes in neoplastic and non-neoplastic gastric epithelia. Cancer Sci. 2003;94:360-. CrossRef
  26. Kang HC, et al. Promoter hypermethylation and silencing of CHFR mitotic stress checkpoint gene in human gastric cancers. Oncol Rep. 2004;12:129-3.
  27. Morioka Y, et al. Aberrant methylation of the CHFR gene in digestive tract cancer. Anticancer Res. 2006;26:1791-.
  28. Kim WJ, Bae SC. Molecular biomarkers in urothelial bladder cancer. Cancer Sci. 2008;99:646-2. CrossRef
  29. Kim EJ, et al. Methylation of the RUNX3 promoter as a potential prognostic marker for bladder tumor. J Urol. 2008;180:1141-. CrossRef
  30. Privette LM, Gonzalez ME, Ding L, Kleer CG, Petty EM. Altered expression of the early mitotic checkpoint protein, CHFR, in breast cancers: implications for tumor suppression. Cancer Res. 2007;67:6064-4. CrossRef
  
• 作者单位：Shi-Lian Hu (1) (2)
  Da-Bing Huang (1) (2)
  Yu-Bei Sun (3)
  Lei Wu (4)
  Wei-Ping Xu (4)
  Shi Yin (1) (2)
  Jiong Chen (1) (2)
  Xiao-Dong Jiang (1) (2)
  Gan Shen (5)
  
  1. Centre for the study of Gastric Cancer, Anhui Provincial Hospital, Anhui Medical University, 17# Lujiang Road, 230001, Hefei, People’s Republic of China
  2. Department of Gerontology, Anhui Provincial Hospital, Anhui Medical University, 230001, Hefei, People’s Republic of China
  3. Department of Oncology, Anhui Provincial Hospital, Anhui Medical University, 230001, Hefei, People’s Republic of China
  4. Anhui Evidence-based Medicine Center, 230001, Hefei, People’s Republic of China
  5. Cadre’s Ward of Anhui PPC Hospital, 230001, Hefei, People’s Republic of China
  

文摘

Runx3 and CHFR genes were defined as tumor suppressor genes in gastric cancer (GC) recently. This paper was to investigate the roles of methylation and expression status of Runx3 and CHFR genes in GC patients. Methylation-specific polymerase chain reaction (MSP) and bisulfite DNA sequencing (BSP) were used to detect methylation status of Runx3 and CHFR genes in GC patients. The expression of Runx3 and CHFR in GC patients was analyzed by reverse transcription polymerase chain reaction (RT–PCR) and immunohistochemical analysis. The expression of the protein and mRNA decreased remarkably in the patients with aberrant promoter methylation of Runx3 and CHFR genes. The methylation status of Runx3 and CHFR were inversely related to the tumor size, tumor invasion depth and tumor differentiation in GC patients. Moreover, the protein expression of Runx3 and CHFR were significantly correlated with tumor invasion depth and tumor differentiation, respectively. Aberrant promoter methylation of Runx3 and CHFR genes may be involved in the carcinogenesis and development of GC and may provide useful clues for the prediction of the malignant behaviors of GC.